[1] |
Anstee QM, Reeves HL, Kotsiliti E, et al. From NASH to HCC: current concepts and future challenges [J]. Nat Rev Gastroenterol Hepatol, 2019, 16(7): 411-428.
|
[2] |
Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention [J]. Nat Rev Gastroenterol Hepatol, 2017, 15(1): 11-20.
|
[3] |
Hu H, Lin A, Kong M, et al. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives [J]. J Gastroenterol, 2020, 55(2): 142-158.
|
[4] |
Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholic Steatohepatitis: A Review [J]. JAMA, 2020, 323(12): 1175-1183.
|
[5] |
Lebeaupin C, Vallée D, Hazari Y, et al. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease [J]. J Hepatol, 2018, 69(4): 927-947.
|
[6] |
Kim Y, Natarajan SK, Chung S. Gamma-tocotrienol attenuates the hepatic inflammation and fibrosis by suppressing endoplasmic reticulum stress in mice [J]. Mol Nutr Food Res, 2018, 62(21): e1800519.
|
[7] |
Han CY, Rho HS, Kim A, et al. FXR inhibits endoplasmic reticulum stress-induced NLRP3 inflammasome in hepatocytes and ameliorates liver injury [J]. Cell Rep, 2018, 24(11): 2985-2999.
|
[8] |
Wang T, Fu X, Chen Q, et al. Arachidonic acid metabolism and kidney inflammation [J]. Int J Mol Sci, 2019, 20(15): 3683.
|
[9] |
Zhou Y, Liu T, Duan J-X, et al. Soluble epoxide hydrolase inhibitor attenuates lipopolysaccharide-induced acute lung injury and improves survival in mice [J]. Shock, 2017, 47(5): 638-645.
|
[10] |
Gartung A, Yang J, Sukhatme VP, et al. Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor [J]. Proc Natl Acad Sci U S A, 2019, 116(5): 1698-1703.
|
[11] |
Dileepan M, Rastle-Simpson S, Greenberg Y, et al. Effect of dual sEH/COX-2 inhibition on allergen-induced airway inflammation [J]. Front Pharmacol, 2019, 10: 1118.
|
[12] |
Zhang CY, Duan JX, Yang HH, et al. COX-2/sEH dual inhibitor PTUPB alleviates bleomycin-induced pulmonary fibrosis in mice via inhibiting senescence [J]. FEBS J, 2020, 287(8): 1666-1680.
|
[13] |
Liu TG, Sha KH, Zhang LG, et al. Protective effects of alpinetin on lipopolysaccharide/d-Galactosamine-induced liver injury through inhibiting inflammatory and oxidative responses [J]. Microb Pathog, 2019, 126: 239-244.
|
[14] |
Qi J, Kim JW, Zhou Z, et al. Ferroptosis affects the progression of nonalcoholic steatohepatitis via the modulation of lipid peroxidation-mediated cell death in mice [J]. Am J Pathol, 2020, 190(1): 68-81.
|
[15] |
Li CX, Gao JG, Wan XY, et al. Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease via the Sirt1/AMPK and NF-kappaB signaling pathways [J]. World J Gastroenterol, 2019, 25(34): 5120-5133.
|
[16] |
Li X, Shi Z, Zhu Y, et al. Cyanidin-3-O-glucoside improves non-alcoholic fatty liver disease by promoting PINK1-mediated mitophagy in mice [J]. Br J Pharmacol, 2020, 177(15): 3591-3607.
|
[17] |
Love S, Mudasir MA, Bhardwaj SC, et al. Long-term administration of tacrolimus and everolimus prevents high cholesterol-high fructose-induced steatosis in C57BL/6J mice by inhibiting de-novo lipogenesis [J]. Oncotarget, 2017, 8(69): 113403-113417.
|
[18] |
Li G, Zhou F, Chen Y, et al. Kukoamine A attenuates insulin resistance and fatty liver through downregulation of Srebp-1c [J]. Biomed Pharmacother, 2017, 89: 536-543.
|
[19] |
Kolodziejczyk AA, Zheng D, Shibolet O, et al. The role of the microbiome in NAFLD and NASH [J]. EMBO Mol Med, 2019, 11(2): e9302.
|
[20] |
Watt MJ, Miotto PM, De Nardo W, et al. The liver as an endocrine organ-linking NAFLD and insulin resistance [J]. Endocr Rev, 2019, 40(5): 1367-1393.
|
[21] |
Hwang SH, Wagner KM, Morisseau C, et al. Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase [J]. J Med Chem, 2011, 54(8): 3037-3050.
|
[22] |
Zhang YF, Sun CC, Duan JX, et al. A COX-2/sEH dual inhibitor PTUPB ameliorates cecal ligation and puncture-induced sepsis in mice via anti-inflammation and anti-oxidative stress [J]. Biomed Pharmacother, 2020, 126: 109907.
|
[23] |
Hye Khan MA, Hwang SH, Sharma A, et al. A dual COX-2/sEH inhibitor improves the metabolic profile and reduces kidney injury in Zucker diabetic fatty rat [J]. Prostaglandins Other Lipid Mediat, 2016, 125: 40-47.
|
[24] |
Yang HH, Duan JX, Liu SK, et al. A COX-2/sEH dual inhibitor PTUPB alleviates lipopolysaccharide-induced acute lung injury in mice by inhibiting NLRP3 inflammasome activation [J]. Theranostics, 2020, 10(11): 4749-4761.
|
[25] |
Castro RE, Diehl AM. Towards a definite mouse model of NAFLD [J]. J Hepatol, 2018, 69(2): 272-274.
|
[26] |
Verbeek J, Lannoo M, Pirinen E, et al. Roux-en-y gastric bypass attenuates hepatic mitochondrial dysfunction in mice with non-alcoholic steatohepatitis [J]. Gut, 2015, 64(4): 673-683.
|
[27] |
Schwarz DS, Blower MD. The endoplasmic reticulum: structure, function and response to cellular signaling [J]. Cell Mol Life Sci, 2015, 73(1): 79-94.
|
[28] |
Schuster S, Cabrera D, Arrese M, et al. Triggering and resolution of inflammation in NASH [J]. Nat Rev Gastroenterol Hepatol, 2018, 15(6): 349-364.
|
[29] |
Sahin E, Bagci R, Bektur Aykanat NE, et al. Silymarin attenuated nonalcoholic fatty liver disease through the regulation of endoplasmic reticulum stress proteins GRP78 and XBP-1 in mice [J]. J Food Biochem, 2020, 44(6): e13194.
|